Zymeworks Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Vancouver, BC Canada
Total Funding:$125.9M
Industry:Biotech
Founded:2003
Lead Investor(s):Citigroup Global Markets Canada Inc
Press
Claim your profile

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Zymeworks's estimated annual revenue is currently $53M per year.
  • Zymeworks received $110.6M in venture funding in June 2018.
  • Zymeworks's estimated revenue per employee is $173,833
  • Zymeworks's total funding is $125.9M.

Employee Data

  • Zymeworks has 305 Employees.
  • Zymeworks grew their employee count by 30% last year.
  • Zymeworks currently has 23 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Sierra Oncology
$9.8M82-4%N/A
Zymeworks
$53M30530%N/A
Aurinia Pharmac...
$31M200223%N/A
AbCellera
$19.8M12851%N/A
Aspect Biosyste...
$7.6M4932%N/A
Missing a competitor? Contribute!?
Submit

Zymeworks Inc. (NYSE/TSX: ZYME) is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics. Zymeworks suite of complementary therapeutic platforms and its fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated product candidates. Zymeworks lead product candidate, ZW25, is a novel bispecific antibody currently being evaluated in an adaptive Phase 1 clinical trial. Zymeworks second candidate, ZW49, is a bispecific antibody-drug conjugate (ADC) and is expected to be the subject of an Investigational New Drug (IND) filing in 2018. Zymeworks is also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. In addition to Zymeworks wholly owned pipeline, its therapeutic platforms have been further leveraged through multiple strategic partnerships with global pharmaceutical companies: Merck, Eli Lilly, Celgene, GSK, Daiichi Sankyo, and Janssen.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power

305

Number of Employees

$53M

Revenue (est)

23

Current Jobs

30%

Employee Growth %

$125.9M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Executive Contacts

NameTitleEmail
Johnny KwanSenior ManagerEmail Available
Jacque WilkDirectorEmail Available
Mark HollywoodSvp, Technical & Mfg OperationsEmail Available
Hollings RentonMember Board Of Directors
Susan ParkerPrincipal SAS ProgrammerEmail Available
Nels RoyerAssociate Director, Clinical Program ManagementEmail Available
Rose LaiSenior Medical DirectorEmail Available
Patrick KaminkerAssociate Director of Oncology Email Available
Allison FortenberryClinical Trials ManagerEmail Available
Rupert DaviesDirector, PharmacokineticsEmail Available

Zymeworks News

12-Sep-19 - Trianni, Inc. Announces License Agreement with Zymeworks ...

SAN FRANCISCO, Sept. 10, 2019 /PRNewswire/ -- Trianni, Inc. ("TRIANNI") announced today that it has entered into a license agreement with ...

12-Sep-19 - Advisor Group Inc. Raises Holdings in Zymeworks Inc (NYSE:ZYME)

Advisor Group Inc. lifted its holdings in shares of Zymeworks Inc (NYSE:ZYME) by 42.7% during the second quarter, according to its most recent ...

31-Aug-19 - Zymeworks to Participate in Upcoming Investor Conferences

VANCOUVER, British Columbia--(BUSINESS WIRE)--. Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company ...

Zymeworks Funding

DateAmountRoundLead InvestorsReference
2018-06-12$110.6MUndisclosedCitigroup Global Markets Canada IncArticle

Zymeworks Executive Hires

DateNameTitleReference
2018-09-20Anthony PolverinoEVP Early Development/Chief Scientific OfficerArticle